287
Participants
Start Date
May 31, 2012
Primary Completion Date
March 18, 2014
Study Completion Date
March 18, 2014
ASP3652
Oral
Placebo
Oral
Site: 5601, Riga
Site: 5603, Riga
Site: 5103, Brussels
Site: 5101, Antwerp
Site: 5301, Herlev
Site: 5602, Liepāja
Site: 5302, Næstved
Site: 5303, Aarhus
Site: 6303, Vilnius
Site 6204, Málaga
Site: 5402, Holzminden
Site 6202, Laguna
Site: 5406, Duisburg
Site: 6304, Kaunas
Site: 5405, Mainz
Site: 5409, Frankfurt am Main
Site: 5404, Nürtingen
Site 5410, Kirchheim
Site: 5414, Offenburg
Site: 5403, Emmendingen
Site 6108, Moscow
Site 6103, Moscow
Site: 6111, Moscow
Site 6106, Moscow
Site 6101, Moscow
Site 6102, Saint Petersburg
Site 6006, Brasov
Site 6001, Târgu Mureş
Site 6005, Iași
Site: 5202, Kralove
Site: 5203, Kroměříž
Site: 5206, Olomouc
Site: 5209, Pilsen
Site: 5210, Sternberk
Site: 5201, Uherské Hradiště
Site: 6302, Vilnius
Site: 6301, Vilnius
Site: 5706, Amsterdam
Site: 5703, Maastricht
Site: 5701, Nijmegen
Site: 5702, Winterswijk
Site: 5704, Zwijndrecht
Site: 5807, Bialystok
Site 5806, Bydgoszcz
Site: 5811, Chorzów
Site: 5801, Lodz
Site: 5805, Piaseczno
Site: 5812, Poznan
Site: 5802, Warsaw
Site: 5804, Warsaw
Site: 5803, Warsaw
Site 5902, Coimbra
Site 5903, Porto
Site 5901, Porto
Site 6003, Bucharest
Site 6004, Bucharest
Site 6007, Bucharest
Site 6002, Bucharest
Site 6203, Barcelona
Site 6201, Barcelona
Astellas Pharma Europe B.V.
INDUSTRY